<DOC>
	<DOCNO>NCT01659242</DOCNO>
	<brief_summary>In rheumatoid arthritis patient active disease despite optimal treatment methotrexate , main objective pilot study use advance imaging tool magnetic resonance image ultrasound evaluate treatment option efficacious : initiating methotrexate/sulfasalazine combination therapy , switch leflunomide monotherapy</brief_summary>
	<brief_title>Leflunomide Versus Sulfasalazine/Methotrexate Rheumatoid Arthritis : Ultrasound/Magnetic Resonance Imaging Study</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<mesh_term>Sulfasalazine</mesh_term>
	<criteria>Inclusion Criteria 1 . Male female patient age 21 65 year . 2 . Patients childbearing potential ( For example postmenopausal sterilise ) decide offspring ( ) . 3 . All female patient must consent get pregnant/breastfeed , male patient must consent father child must consent practice effective birth control . 4 . Fulfills either 1987 ACR criterion and/or 2010 ACR / EULAR RA Classification Criteria . 5 . Seropositivity : Rheumatoid factor ( RF ) and/or anti cyclic citrullinated protein antibody ( antiCCP ) must positive . 6 . MCPJ ( ) and/or Wrist ( ) joint ( ) involvement . 7 . Rheumatoid arthritis patient ( less 5 year duration ) remain least moderately active base DAS28 score &gt; 3.2 , follow 3 month therapy optimal dose methotrexate ( e.g . least 15 mg/week ) . 8 . If patient oral corticosteroid , exceed 10mg prednisolone daily ( oral steroid equivalent ) least 4 week unchanged dose least 2 week enter study . 9 . If patient NSAIDs , unchanged dose least 2 week enter study . 10 . Glomerular filtration rate &gt; 60 mls/min/1.73m2 . Exclusion Criteria 1 . Patient known follow medical condition ( ) exclude : 1 . Other autoimmune disease /inflammatory joint disease/connective tissue disease ( e.g . lupus , seronegative spondylarthropathy ( e.g . ankylose spondylitis/psoriatic arthropathy ) , reactive arthritis , overlap syndrome , primary sjogren syndrome mixed connective tissue disease . ) 2 . Inflammatory arthritis onset 18 year old . 3 . Current previous history cancer lymphoproliferative disease . 4 . HIV positive status , Hepatitis B/C positive status . 5 . Persistent and/or severe infection previous 12 week . 6 . Major traumatic injury , terminal illness , medical condition ( ) could place patient risk participate study . 7 . Clinically relevant cardiovascular ( e.g unstable ischemic heart disease ) , neurological ( e.g recent stroke ) , gastroenterology ( e.g active peptic ulcer disease ) , renal ( e.g chronic renal failure ) , hepatic ( e.g alcoholic liver disease , fatty liver ) major systemic disease could ) place patient risk participate study ; ii ) make protocol implementation difficult ; iii ) make study result interpretation difficult . 8 . Presence known condition ( ) /circumstance ( ) would negatively impact compliance study completion . 2 . Impaired laboratory parameter : 1 . Hemoglobin le 10.5 g/dl , white blood count le 4 x 10 ( 9 ) /L , platelet count le 150 x 10 ( 9 ) /L . 2 . Deranged Liver function test : e.g . elevate AST/ALT . 3 . Wants consume alcohol take study medication . 4 . Body weight less 45 kg . 5 . Pregnancy/Breastfeeding/Male patient wish father child . 6 . Patients follow medication history exclude : 1 . History Glucose 6 Phosphate Dehydrogenase ( G6PD ) deficiency . 2 . Known allergy : ) study medication ; ii ) contrast ; iii ) drug whose chemical structure similar ( e.g . sulphonamides , salicylate , etc ) . 3 . On anticoagulation reason . 4 . Previous treatment ( within last 4 week ) : ) oral corticosteroid great prednisolone equivalent 10mg/day ; ii ) parenteral/intraarticular corticosteroid injection . 5 . Previous treatment ( within last 12 week ) : ) DMARDs sulfasalazine , hydroxychloroquine , chloroquine , gold salt , etc ; ii ) investigational drug ( ) ; iii ) immunosuppressive agent cyclophosphamide , cyclosporin , azathioprine biologic agent , e.g . antiTNF . 6 . Previous treatment ( duration ) ) Leflunomide ; ii ) Sulfasalazine use together methotrexate 7 . Contraindication MRI ( e.g . pacemaker , metallic implants/stents , claustrophobia ) .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Ultrasound</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
</DOC>